Lymphoma Program News Today

Or any of its ingredients. Competition changes lives. That really captivates people. Stop taking victoza® and get medical help right away its been said that its made and what to do about as women, we need to take time to be active. If you get symptoms of a serious allergic reaction such as rash, thats whats so amazing about poise® impressa. Grown men cry. You call it your secret joy, technologys unintended i can wear this nice dress and i dont have to wear a pad now. Swelling, difficulty breat...

Initial data from 15 patients with relapsed/refractory marginal zone lymphoma show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA® All patients...

Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.

Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

Despite concerns about the development of secondary T-cell malignancies due to CAR T-cell immunotherapy, experts still believed that the benefits outweigh the risks.

Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.

<p><strong>PHILADELPHIA – </strong>The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in <a href="https://www.nature.com/articles/s41591-024-02826-w"><em>Nature Medicine</em></a>. The team also described a single case o...

Joanna M. Rhodes, MD, MSCE, discusses the safety and efficacy of treatment with pirtobrutinib following exposure to a covalent BTK inhibitor in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.